While hormone therapy remains the most effective treatment for hot flashes and many other perimenopause symptoms, it is not an option for everyone. Some women have medical contraindications (like a history of breast cancer or blood clots). Others simply prefer not to use hormones. Either way, you are not without good options.
The landscape of non-hormonal treatments has changed dramatically in recent years. The North American Menopause Society now recognizes several non-hormonal options as effective alternatives. Two new medications have been specifically designed and FDA-approved for menopausal hot flashes, and several off-label medications have solid evidence behind them. Here is what works, how each option works, and who each one is best suited for.
The New Generation: NK3 Receptor Antagonists
These represent the most significant advance in non-hormonal menopause treatment in decades. They work by targeting the neurokinin 3 (NK3) receptor in the brain’s thermoregulatory center, the same pathway that becomes dysregulated when estrogen declines, causing hot flashes and night sweats. Cleveland Clinic's perimenopause resource provides a helpful overview of how these hormonal changes trigger symptoms.
Elinzanetant (Lynkuet)
FDA-approved in November 2025, elinzanetant is the newest non-hormonal option and represents a meaningful improvement over its predecessor.
- How it works: A dual NK1/NK3 receptor antagonist. By blocking both neurokinin pathways, it addresses hot flashes and sleep disruption, a significant advantage, since sleep problems are often as debilitating as the hot flashes themselves.
- Effectiveness: Clinical trials showed significant reduction in both the frequency and severity of hot flashes, with additional improvements in sleep quality.
- Key advantage: Does not require routine liver monitoring, which is a significant practical advantage over fezolinetant.
- Side effects: Generally well-tolerated. Most common side effects in trials were mild and included headache and fatigue.
Fezolinetant (Veozah)
FDA-approved in 2023, fezolinetant was the first medication in this new class.
- How it works: A selective NK3 receptor antagonist that targets the brain’s temperature control center.
- Effectiveness: Reduces hot flash frequency by approximately 50-60% and severity significantly in clinical trials.
- Important requirement: Requires liver function testing before starting and periodically during treatment due to a small risk of liver injury. This is the main practical drawback compared to elinzanetant.
- Side effects: Most common include abdominal pain, diarrhea, insomnia, and back pain.
Fezolinetant Liver Monitoring
If you are prescribed fezolinetant (Veozah), your doctor should check your liver function before starting the medication and at 3, 6, and 9 months during the first year. Report any signs of liver problems (unusual fatigue, nausea, dark urine, yellowing of skin or eyes) to your doctor promptly.
SSRIs and SNRIs (Off-Label)
Certain antidepressants have been found to reduce hot flash frequency by 25-50%, even in women who are not depressed. For women who can use hormones, hormone therapy remains more effective, but these medications fill an important gap. They work by modulating serotonin and norepinephrine, neurotransmitters involved in the brain’s temperature regulation.
- Paroxetine (low-dose/Brisdelle): The only SSRI FDA-approved for hot flashes (at a 7.5 mg dose, lower than the antidepressant dose). Reduces hot flash frequency by approximately 33-50%.
- Venlafaxine (Effexor): An SNRI with good evidence for hot flash reduction. Also helps with mood and anxiety, making it a good choice for women dealing with both.
- Escitalopram (Lexapro) and citalopram (Celexa): Both have shown effectiveness in clinical trials for hot flash reduction.
Who they are best for: Women who experience significant mood or anxiety symptoms alongside hot flashes may get dual benefit from these medications. They are also a good option for women with a history of breast cancer, for whom HRT is typically contraindicated.
Important note: Paroxetine should not be used by women taking tamoxifen for breast cancer, as it interferes with tamoxifen metabolism.
Gabapentin and Pregabalin
Originally developed for seizures and nerve pain, gabapentin has been found to reduce hot flash frequency by approximately 30-50%.
- Best for: Women whose primary issue is night sweats and sleep disruption. Gabapentin has a sedative effect that can be beneficial when taken at bedtime.
- Dosing: Typically 300-900 mg at bedtime for hot flashes (lower than doses used for pain or seizures).
- Side effects: Drowsiness (which can be a benefit at night), dizziness, and fatigue. These usually improve over the first 1-2 weeks.
- Pregabalin (Lyrica): Similar mechanism with evidence for hot flash reduction. May also help with joint pain and sleep.
CBT for Hot Flashes
Cognitive Behavioral Therapy specifically designed for hot flashes (not general CBT) has strong clinical evidence. It does not reduce the physiological hot flash itself but significantly changes how distressing and disruptive hot flashes feel. Research from King’s College London showed that women who completed a CBT program reported significantly less bother from hot flashes and better sleep, even though the actual number of hot flashes remained similar.
For a deeper look at CBT and other mind-body approaches, see our guide to behavioral and mind-body therapies for perimenopause.
How to Choose
The right non-hormonal medication depends on your specific situation:
- Hot flashes as primary concern: Elinzanetant (Lynkuet) or fezolinetant (Veozah) are the most effective non-hormonal options specifically designed for this purpose.
- Hot flashes + mood/anxiety: An SSRI or SNRI may address both simultaneously.
- Night sweats + sleep disruption: Gabapentin at bedtime or elinzanetant (which also improves sleep) may be ideal.
- Breast cancer history: SSRIs (except paroxetine if on tamoxifen), elinzanetant, or fezolinetant are options. Discuss with your oncologist.
- Prefer non-medication approach: CBT for hot flashes combined with lifestyle changes can provide meaningful relief.
What Non-Hormonal Medications Don’t Do
It is important to be clear about limitations. Non-hormonal medications are primarily effective for hot flashes and night sweats. They do not address:
- Vaginal dryness and atrophy (local vaginal estrogen is needed for this)
- Bone loss prevention (only HRT and specific osteoporosis medications do this)
- The potential neuroprotective and cardiovascular benefits associated with HRT
If your symptoms extend beyond hot flashes, a combination approach that pairs non-hormonal medications with lifestyle changes, local vaginal estrogen, and/or supplements may serve you best.
The Bottom Line
If you can’t or prefer not to use hormone therapy, you still have effective options. The NK3 receptor antagonists (elinzanetant and fezolinetant) represent a genuine breakthrough. Combined with the right off-label medications and behavioral approaches, non-hormonal treatment can provide meaningful relief for the most disruptive perimenopause symptoms.